57 recruiting. 57 Phase 2, 15 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 57 | Recruiting 57 |
| Phase 1 | 15 | Recruiting 15 |
| Phase 3 | 4 | Recruiting 4 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis PRO-1562 Oral Capsules, Placebo Oral Capsule - Multiple Sclerosis | Phase 1 / Phase 2 | Recruiting | Progentos Therapeutics | 160 | 2026-10-01 | 2026-09-29 |
| A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS) SUN-627, Placebo - Primary Progressive Multiple Sclerosis, Primary Progressive MS | Phase 2 | Recruiting | Sundance Biosciences, Inc. | 20 | 2026-10-01 | 2026-10-30 |
| The HIt HArd and hiT Early in Multiple Sclerosis Trial Sequential treatment with rituximab and cladribine - Relapsing-remitting Multiple Sclerosis | Phase 2 | Recruiting | Uppsala University | 60 | 2026-09-01 | 2026-10-22 |
| A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis Terfenadine, Standard First-line Disease-Modifying Therapy - Relapsing Remitting Multiple Sclerosis | Phase 2 | Recruiting | Chuan Qin | 100 | 2026-08-15 | 2026-09-18 |
| A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis Rocbrutinib, Dimethyl Fumarate - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 30 | 2026-08-01 | 2026-08-20 |
| Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study Brincidofovir - Progressive Multifocal Leukoencephalopathy | Phase 2 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 24 | 2026-06-05 | 2026-07-22 |
| Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis HP 13C pyruvate injection, MRI Scanner - Multiple Sclerosis, RRMS | Phase 2 | Recruiting | Ari Green | 40 | 2026-06-03 | 2026-06-08 |
| Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis NLY01, Placebo - Multiple Sclerosis | Phase 2 | Recruiting | Johns Hopkins University | 120 | 2026-04-28 | 2026-07-17 |
| MB-CART2019.1 in Refractory Multiple Sclerosis MB-CART2019.1 - Multiple Sclerosis, CAR T Cell Therapy | Phase 1 / Phase 2 | Recruiting | Miltenyi Biomedicine GmbH | 26 | 2026-04-01 | 2026-05-11 |
| A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) Ublituximab, Prefilled pen - Multiple Sclerosis | Phase 2 | Recruiting | TG Therapeutics, Inc. | 350 | 2026-04-01 | 2026-10-29 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) RO7268489, Ocrelizumab, Placebo - Progressive Multiple Sclerosis | Phase 2 | Recruiting | Hoffmann-La Roche | 360 | 2026-03-10 | 2026-10-07 |
| Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis TRX319, Bendamustine - Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS) | Phase 1 / Phase 2 | Recruiting | Tr1X, Inc. | 39 | 2026-03-01 | 2026-09-21 |
| T-cell Therapy in Patients With PML Application of T-lymphocytes - Progressive Multifocal Leucoencephalopathy (PML) | Phase 2 | Recruiting | Hannover Medical School | 23 | 2026-02-06 | 2026-10-15 |
| Cannabis (THC vs. CBD) in Multiple Sclerosis THC, CBD - Multiple Sclerosis | Phase 2 | Recruiting | University of Calgary | 30 | 2025-12-05 | 2026-09-15 |
| Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS) metformin, Placebo - Multiple Sclerosis | Phase 2 | Recruiting | State University of New York at Buffalo | 30 | 2025-09-24 | 2025-11-21 |
| Efgartigimod for the Treatment of Acute Optic Neuritis Efgartigimod Alfa, Placebo - Optic Neuritis | Phase 2 | Recruiting | Anastasia Vishnevetsky, MD, MPH | 20 | 2025-08-12 | 2026-10-28 |
| Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) Active tDCS, Sham tDCS - Multiple Sclerosis, Depression | Phase 2 | Recruiting | NYU Langone Health | 170 | 2025-08-11 | 2026-06-29 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients VT7208, Placebo - Multiple Sclerosis | Phase 1 / Phase 2 | Recruiting | Vidya Therapeutics Inc | 100 | 2025-08-01 | 2026-07-21 |
| RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses RE104 for Injection - Adjustment Disorder | Phase 2 | Recruiting | Reunion Neuroscience Inc | 100 | 2025-07-30 | 2026-09-15 |
| Psilocybin Therapy for Psychological Distress in Palliative Patients Psilocybin therapy - COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis) | Phase 2 | Recruiting | University Medical Center Groningen | 108 | 2025-07-01 | 2026-05-08 |
Showing 20 of 57. Sign in to see all of them.
Multiple Sclerosis (38) · Multiple Sclerosis, Chronic Progressive (8) · Neuromyelitis Optica (6) · Multiple Sclerosis, Relapsing-Remitting (5) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (5) · Amyotrophic Lateral Sclerosis (3) · Depression (3) · Alzheimer Disease (2) · Leukoencephalopathy, Progressive Multifocal (2) · Myelitis, Transverse (2) · Optic Neuritis (2) · Adjustment Disorders (1) · Adrenoleukodystrophy (1) · Anemia, Diamond-Blackfan (1)
Nervous System Diseases (57) · Autoimmune Diseases (53) · Immune System Diseases (53) · Autoimmune Diseases of the Nervous System (52) · Demyelinating Autoimmune Diseases, CNS (49) · Pathological Conditions, Signs and Symptoms (21) · Disease Attributes (16) · Pathologic Processes (16) · Chronic Disease (15) · Central Nervous System Diseases (10) · Eye Diseases (8) · Mental Disorders (8) · Neurodegenerative Diseases (8) · Neuromuscular Diseases (8)
Cannabidiol (2) · Clemastine (2) · Dronabinol (2) · Injections (2) · Metformin (2) · Methylprednisolone (2) · Prednisone (2) · Rituximab (2) · Solutions (2) · 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific) (1) · Alemtuzumab (1) · BCG Vaccine (1) · Bendamustine Hydrochloride (1) · Cilostazol (1) · Cladribine (1)
Brigham and Women's Hospital (2) · Johns Hopkins University (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · University of California, San Francisco (2) · Amgen (1) · Anastasia Vishnevetsky, MD, MPH (1) · Ari Green (1) · Ashvattha Therapeutics, Inc. (1) · Aspa Therapeutics (1) · Cairo University (1) · Celgene (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Chuan Qin (1) · Clinical Academic Center (2CA-Braga) (1) · Ever Supreme Bio Technology Co., Ltd. (1)
United States (30) · Canada (8) · Poland (8) · Australia (7) · China (7) · Germany (7) · United Kingdom (6) · Portugal (5) · Denmark (4) · France (4) · Italy (4) · Serbia (4) · Spain (4) · Argentina (3) · Brazil (3)
Amr Hassan Elsayed, MD Neurology (1) · Anastasia Vishnevetsky, MD, MPH (1) · Ari Green, MD (1) · Ari Green, MD, MCR (1) · Ari J Green, MD, MCR (1) · Bardia Nourbakhsh, MD (1) · Benjamin Greenberg, MD (1) · Bibiana Bielekova, M.D. (1) · Chuan Qin (1) · Daniel S Reich, M.D. (1) · De-Cai Tian, M.D., Ph.D. (1) · E. Ann Yeh, MA, MD, FRCPC, Dip ABPN (1) · Ellen M Mowry, MD, MCR (1)
PMID 32600454, PMID 32634238, PMID 32750127, PMID 37310119, PMID 38630948, PMID 39114536, PMID 40371642
2023 (3), 2025 (2), R01AT011341 (1), R01NS102156 (1), UL1TR001412 (1)